This database contains 140 studies, archived under the term: "UK"
Click here to filter this large number of results.
Validation of Alzheimer’s disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI)
Buerger, Katharina,
Frisoni, Giovanni,
Uspenskaya, Olga,
Ewers, Michael,
Zetterberg, Henrik,
Geroldi, Cristina,
Binetti, Giuliano,
Johannsen, Peter,
Rossini, Paolo Maria,
Wahlund, Lars-Olof,
Vellas, Bruno,
Blennow, Kaj,
Hampel, Harald
Background: Alzheimer’s Disease Neuroimaging Initiatives (“ADNI”) aim to validate neuroimaging and biochemical markers of Alzheimer’s disease (AD). Data of the pilot European-ADNI (E-ADNI) biological marker programme of cerebrospinal fluid (CSF) and plasma candidate biomarkers are reported.; Methods: Six academic EADC centres recruited 49 subjects (healthy controls, subjects with mild cognitive impairment (MCI) and AD). We […]
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial
Banerjee, Sube,
Hellier, Jennifer,
Dewey, Michael,
Romeo, Renee,
Ballard, Clive,
Baldwin, Robert,
Bentham, Peter,
Fox, Chris,
Holmes, Clive,
Katona, Cornelius,
Knapp, Martin,
Lawton, Claire,
Lindesay, James,
Livingston, Gill,
McCrae, Niall,
Moniz-Cook, Esme,
Murray, Joanna,
Nurock, Shirley,
Orrell, Martin,
O'Brien, John,
Poppe, Michaela,
Thomas, Alan,
Walwyn, Rebecca,
Wilson, Kenneth,
Burns, Alistair
Background: Depression is common in dementia but the evidence base for appropriate drug treatment is sparse and equivocal. We aimed to assess efficacy and safety of two of the most commonly prescribed drugs, sertraline and mirtazapine, compared with placebo.; Methods: We undertook the parallel-group, double-blind, placebo-controlled, Health Technology Assessment Study of the Use of Antidepressants […]
The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial
Ballard, Clive,
Hanney, Maria Luisa,
Theodoulou, Megan,
Douglas, Simon,
McShane, Rupert,
Kossakowski, Katja,
Gill, Randeep,
Juszczak, Edmund,
Yu, Ly-Mee,
Jacoby, Robin
Background: Data from 12-week placebo-controlled trials have led to mounting concerns about increased mortality in patients with Alzheimer’s disease (AD) who are prescribed antipsychotics; however, there are no mortality data from long-term placebo-controlled trials. We aimed to assess whether continued treatment with antipsychotics in people with AD is associated with an increased risk of mortality.; […]
Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
Aarsland, Dag,
Ballard, Clive,
Walker, Zuzana,
Bostrom, Fredrik,
Alves, Guido,
Kossakowski, Katja,
Leroi, Iracema,
Pozo-Rodriguez, Francisco,
Minthon, Lennart,
Londos, Elisabet
Background: Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are common forms of dementia that substantially affect quality of life. Currently, the only treatment licensed for PDD is rivastigmine, and there are no licensed treatments for DLB. We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine […]